<code id='6F7C2CB1DD'></code><style id='6F7C2CB1DD'></style>
    • <acronym id='6F7C2CB1DD'></acronym>
      <center id='6F7C2CB1DD'><center id='6F7C2CB1DD'><tfoot id='6F7C2CB1DD'></tfoot></center><abbr id='6F7C2CB1DD'><dir id='6F7C2CB1DD'><tfoot id='6F7C2CB1DD'></tfoot><noframes id='6F7C2CB1DD'>

    • <optgroup id='6F7C2CB1DD'><strike id='6F7C2CB1DD'><sup id='6F7C2CB1DD'></sup></strike><code id='6F7C2CB1DD'></code></optgroup>
        1. <b id='6F7C2CB1DD'><label id='6F7C2CB1DD'><select id='6F7C2CB1DD'><dt id='6F7C2CB1DD'><span id='6F7C2CB1DD'></span></dt></select></label></b><u id='6F7C2CB1DD'></u>
          <i id='6F7C2CB1DD'><strike id='6F7C2CB1DD'><tt id='6F7C2CB1DD'><pre id='6F7C2CB1DD'></pre></tt></strike></i>

          explore

          explore

          author:knowledge    Page View:2678
          Richard Burr
          North Carolina Senator Richard Burr received strong support from the biotech sector. Gerry Broome/AP

          WASHINGTON — A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry.

          North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross.

          advertisement

          Burr, now finishing his second term in the Senate, serves on committees with oversight of both the Food and Drug Administration and Medicare and Medicaid. He is also chairman of the Select Committee on Intelligence.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M
          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

          CytokineticsCEORobertBlumspokelastweekatatalkduringSTAT’sBreakthroughSummitWestinSanFrancisco.SarahG

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Sanofi says it has 12 blockbusters on the way. Will investors believe it?

          SanofiCEOPaulHudsonCourtesySanofiNEWYORK—ThetopexecutivesatFrenchdruggiantSanofionWednesdaydefendedt